Neogen Corporation (NEOG) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Neogen Corporation (NEOG) right now is Recurring food safety testing demand: Food Safety is now roughly 70% of revenue and grew mid-single digits in core terms in recent quarters. Revenue (FY2026 guidance) is ~$857-860M. If that keeps playing out, the setup is favourable; the risk to it is integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. No one can predict where NEOG trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Neogen Corporation (NEOG) higher?
1. Recurring food safety testing demand
Food Safety is now roughly 70% of revenue and grew mid-single digits in core terms in recent quarters. Testing for pathogens, allergens, and toxins is a repeat-consumable business tied to regulatory and quality requirements, which gives Neogen a relatively sticky, recurring revenue base.
2. Deleveraging and portfolio focus
The agreed ~$160 million sale of the genomics business to Zoetis is intended to cut debt, with a stated goal of lowering net debt to adjusted EBITDA below roughly 3x by the end of calendar 2026. Shedding non-core units and directing proceeds to the balance sheet is central to the reset story.
3. Scale from the 3M Food Safety combination
The 3M acquisition widened Neogen's product breadth and customer reach across food-testing categories. If integration stabilizes, the enlarged platform could support cross-selling and operating leverage as one-time merger costs roll off.
4. Guidance revisions and margin recovery
Management raised fiscal 2026 revenue guidance toward ~$857-860 million while targeting adjusted EBITDA around ~$175 million. Whether reported margins and free cash flow follow the adjusted figures higher is a key watch item for the coming year.
What could weigh on NEOG?
Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The company carries elevated leverage and competes against larger, better-capitalized players in both food and animal diagnostics. Core revenue in the Animal Safety segment declined in recent quarters, showing uneven demand. The genomics divestiture removes a ~$90 million revenue line, so the remaining business must carry growth on its own. The stock has been volatile and traded near multi-year lows, so sentiment can swing sharply on quarterly execution.
Where NEOG trades today
A forecast starts from where the stock actually is. These are NEOG's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for NEOG as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a NEOG forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the NEOG guide and whether NEOG is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the NEOG outlook
The bottom line: what is driving Neogen Corporation (NEOG) is Recurring food safety testing demand, with revenue (fy2026 guidance) at ~$857-860M. If that keeps playing out the setup is favourable; the risk is integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. No one can predict the price, so treat any NEOG forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
More on NEOG
- NEOG stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- Is NEOG a buy? (the case for, the risks, and a framework to decide)
- Does NEOG pay a dividend?
Build a basket around NEOG with Walnut
Use Neogen Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Neogen Corporation (NEOG)?
+
No one can reliably predict where NEOG will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Neogen Corporation higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive NEOG higher?
+
The main growth drivers are Recurring food safety testing demand; Deleveraging and portfolio focus; Scale from the 3M Food Safety combination. Whether they play out is the real question, not a guaranteed path.
What are the risks to NEOG?
+
Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The company carries elevated leverage and competes against larger, better-capitalized players in both food and animal diagnostics. Core revenue in the Animal Safety segment declined in recent quarters, showing uneven demand. The genomics divestiture removes a ~$90 million revenue line, so the remaining business must carry growth on its own. The stock has been volatile and traded near multi-year lows, so sentiment can swing sharply on quarterly execution.
Will NEOG stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Neogen Corporation's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is NEOG a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the NEOG "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.